---
document_datetime: 2025-09-10 14:35:57
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vegzelma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vegzelma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.739673
conversion_datetime: 2025-12-24 06:20:28.056647
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vegzelma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 08/09/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000295472                      | Update of the package leaflet with revised contact details of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |                        |                   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-------------------|
| Variation type IB /                   | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Change in the testing frequency of specification parameter, from routine testing to skip or periodic testing - Accepted                                                                                                                                                                                                                                                                                                                                                                          | 05/06/2025 | N/A |                        | EMA/VR/0000271859 |
| Variation type IB / EMA/VR/0000264760 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - to apply editorial changes throughout Product Information as follows: - update of sections 4.4, 4.8 and 5.1 of the SmPC to align with Avastin Product Information; - VEGZELMA revised to Vegzelma according to Compilation of QRD decisions on stylistic matters in product Information; - addition of information regarding polysorbate according to Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'; - http://www.ema.europa.eu revised to https://www.ema.europa.eu according to the latest QRD template version 10.4; - | 22/05/2025 |     | SmPC, Labelling and PL |                   |

<div style=\"page-break-after: always\"></div>

|                                       | addresses of manufacturers revised to align with Section 3.2.P.3.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |                                  |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|
| Variation type IA / EMA/VR/0000258086 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted | 26/03/2025 | N/A | SmPC, Annex II, Labelling and PL |
| Article 61(3) / EMA/N/0000250376      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                             | 03/03/2025 |     | PL                               |